Moderna’s cancer shot: exciting for investors, inconclusive for patients
A glimmer of hope for sufferers, a potential revenue platform for a cash-burner, and a whole heap of unknowns
We haven't written up this one. Financial Times has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.